JAMA Internal Medicine· 2018Q1
Association of a Smartphone Application With Medication Adherence and Blood Pressure Control
- 364citations
- Q1SCImago
- 2018year
Short summary
A 12-week randomized trial (n=411) found the Medisafe smartphone app improved self-reported medication adherence (MMAS score change: 0.4 vs. 0.0) but did not significantly reduce systolic blood pressure (-0.5 mm Hg difference) in patients with uncontrolled hypertension.
AI-generated from the title and abstract; the full text is not read.
Key points
- The Medisafe smartphone app improved self-reported medication adherence by 0.4 points on the MMAS scale over 12 weeks compared to no change in controls (P=.01).
- Systolic blood pressure decreased by 10.6 mm Hg in the app group and 10.1 mm Hg in the control group, with no significant between-group difference (-0.5 mm Hg; P=.78).
- The study randomized 411 participants with uncontrolled hypertension and 1-3 antihypertensive medications.
- Participants were recruited online and mailed a blood pressure cuff.
AI-generated from the title and abstract; the full text is not read.
Abstract
Importance: Medication nonadherence accounts for up to half of uncontrolled hypertension. Smartphone applications (apps) that aim to improve adherence are widely available but have not been rigorously evaluated. Objective: To determine if the Medisafe smartphone app improves self-reported medication adherence and blood pressure control. Design, Setting, and Participants: This was a 2-arm, randomized clinical trial (Medication Adherence Improvement Support App For Engagement-Blood Pressure [MedISAFE-BP]). Participants were recruited through an online platform and were mailed a home blood pressure cuff to confirm eligibility and to provide follow-up measurements. Of 5577 participants who were screened, 412 completed consent, met inclusion criteria (confirmed uncontrolled hypertension, taking 1 to 3 antihypertensive medications), and were randomized in a ratio of 1:1 to intervention or control. Interventions: Intervention arm participants were instructed to download and use the Medisafe app, which includes reminder alerts, adherence reports, and optional peer support. Main Outcomes and Measures: Co-primary outcomes were change from baseline to 12 weeks in self-reported medication adherence, measured by the Morisky medication adherence scale (MMAS) (range, 0-8, with lower scores indicating lower adherence), and change in systolic blood pressure. Results: Participants (n = 411; 209 in the intervention group and 202 controls) had a mean age of 52.0 years and mean body mass index, calculated as weight in kilograms divided by height in meters squared, of 35.5; 247 (60%) were female, and 103 (25%) were black. After 12 weeks, the mean (SD) score on the MMAS improved by 0.4 (1.5) among intervention participants and remained unchanged among controls (between-group difference: 0.4; 95% CI, 0.1-0.7; P = .01). The mean (SD) systolic blood pressure at baseline was 151.4 (9.0) mm Hg and 151.3 (9.4) mm Hg, among intervention and control participants, respectively. After 12 weeks, the mean (SD) systolic blood pressure decreased by 10.6 (16.0) mm Hg among intervention participants and 10.1 (15.4) mm Hg among controls (between-group difference: -0.5; 95% CI, -3.7 to 2.7; P = .78). Conclusions and Relevance: Among individuals with poorly controlled hypertension, patients randomized to use a smartphone app had a small improvement in self-reported medication adherence but no change in systolic blood pressure compared with controls. Trial Registration: clinicaltrials.gov Identifier: NCT02727543.
The authors' abstract, as published at the source. JAMA Internal Medicine, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Family Practice
Family PracticeMedicine